Jump to content

GENENTECH TO PRESENT FIRST CLINICAL DATA ON NOVEL ANTI-TIGIT CANCER IMMUNOTHERAPY TIRAGOLUMAB AT ASCO


Recommended Posts

Press Release: 

GENENTECH TO PRESENT FIRST CLINICAL DATA ON NOVEL ANTI-TIGIT CANCER IMMUNOTHERAPY TIRAGOLUMAB AT ASCO

PHASE II CITYSCAPE TRIAL SHOWS PROMISING RESULTS ADDING TIRAGOLUMAB TO TECENTRIQ IN PEOPLE WITH PD-L1-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCERFULL RESULTS WILL BE PRESENTED IN AN ORAL ABSTRACT SESSION AT THE ASCO20 VIRTUAL SCIENTIFIC PROGRAM ORGANIZED BY THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO)

https://www.gene.com/media/press-releases/14852/2020-05-13/genentech-to-present-first-clinical-data

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
×
  • Create New...

Important Information

By using this site, you agree to our Terms of Use.